Reports of esophageal cancer with oral bisphosphonate use

New England Journal of Medicine

Volumn 360, Issue 1, 2009, Pages 89-90

  Wysowski, Diane K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DRUG EXPOSURE; ESOPHAGITIS; ESOPHAGUS CANCER; HISTOPATHOLOGY; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; AGED; CHEMICALLY INDUCED DISORDER; ESOPHAGUS TUMOR; EUROPE; FEMALE; JAPAN; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; EUROPE; FEMALE; HUMANS; JAPAN; MALE; RISK FACTORS; UNITED STATES;

EID: 58249090943     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0808738     Document Type: Letter

References (5)

1. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90.
2. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
3. Ryan JM, Kelsey P, Ryan BM, Mueller PR. Alendronate- induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture - radiographic features. Radiology 1998;206:389-91.
4. Ribeiro A, DeVault KR, Wolfe JT III, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-8.
5. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu T-T. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999;12:1152-7.